Nov 23, 2021

November 23, 2021 08:37 AM Eastern Standard Time When faced with an outbreak of a pathogen with no known treatments, we are forced to rely on the pharmaceutical industry to develop interventions to curb these potential disasters. The COVID-19 Clinical and Commercial Analyzer is an interactive Excel-based tool that scores leading pipeline-stage vaccines and therapeutics on a range of clinical and commercial parameters based on available clinical data. The catalyst for the initial release of this analysis, dated September 15, 2021, includes all clinical data readouts and other market-altering events that have occurred since the outbreak's inception. Key Highlights Competitive Assessment: Visual representation of the results of the analyzer, depicting how the leading candidates compete. Product Dashboard: Compilation of all key product features, plus a proprietary SWOT analysis of each product. Clinical Data Summary: Listing of published clinical data for all products included in the analysis. Scope Catalyst: Description of the most recent events impacting the COVID-19 R&D competitive landscape that are accounted for in the analysis Scope of Coverage and Methodology: Discussion of product inclusion criteria and outline of rationale and assumptions Clinical and Commercial Analyzer: Each asset is scored on a set of characteristics that will determine their post-launch success, including clinical features such as efficacy, safety, and dosing regimen and commercial attributes such as price, company reputation, and marketing and sales force strength Competitive Assessment: Visual representation of the results of the analyzer, depicting how the leading candidates compete Product Dashboard: Compilation of all key product features, plus a proprietary SWOT analysis of each product Clinical Data Summary: Listing of published clinical data for all products included in the analysis Key Topics Covered: 1.3 Monitor the COVID-19 Outbreak with The Publisher Epidemiology Indicators 2 Epidemiology 2.2 Epidemiology: Disease Trajectory as of March 25, 2020 2.3 Epidemiology Indicators in the Top 3 Most-Affected Countries: Disease Trajectory in China as of March 25, 2020 2.4 Epidemiology Indicators in the Top 3 Most-Affected Countries: Disease Trajectory in Italy as of March 25, 2020 2.5 Epidemiology Indicators in the Top 3 Most-Affected Countries: Disease Trajectory in the US as of March 25, 2020 2.6 Epidemiology Forecast: United States 3 Pipeline Overview 3.2 Pipeline Therapeutics: Breakdown by Molecule Type 3.3 Pipeline Therapeutics: Breakdown by Type of Developer 3.4 Pipeline Therapeutics: Clinical-Stage Candidates (Phase I - III) 3.5 Pipeline Therapeutics: Preclinical-Stage Candidates 3.6 Pipeline Therapeutics: Currently Available Data 3.7 Pipeline Vaccines: Breakdown by Phase 3.8 Pipeline Vaccines: Breakdown by Developer Type 3.9 Pipeline Vaccines: Clinical and Preclinical-Stage Candidates 4 Pipeline Overview 4.2 Pipeline Therapeutics: Breakdown by Molecule Type 4.3 Pipeline Therapeutics: Breakdown by Type of Developer 4.4 Pipeline Therapeutics: Clinical-Stage Candidates (Phase I - III) 4.5 Pipeline Therapeutics: Preclinical-Stage Candidates 4.6 Pipeline Therapeutics: Currently Available Data 4.7 Pipeline Vaccines: Breakdown by Phase 4.8 Pipeline Vaccines: Breakdown by Developer Type 4.9 Pipeline Vaccines: Clinical and Preclinical-Stage Candidates 5 Clinical Trials 5.2 Clinical Trials for Therapeutics and Vaccines 5.3 Clinical Trials: Overview by Region 5.4 Clinical Trials for Therapeutics: Leading Sponsors 5.5 Clinical Trials: Leading Industry Sponsors 5.6 Trends in Trial Design 6 Deal-making Trends